<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Trials</journal-id><journal-id journal-id-type="iso-abbrev">Trials</journal-id><journal-title-group><journal-title>Trials</journal-title></journal-title-group><issn pub-type="epub">1745-6215</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28693594</article-id><article-id pub-id-type="pmc">5504754</article-id><article-id pub-id-type="publisher-id">2051</article-id><article-id pub-id-type="doi">10.1186/s13063-017-2051-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>The impact of phosphate-balanced crystalloid infusion on acid-base homeostasis (PALANCE study): study protocol for a randomized controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3605-955X</contrib-id><name><surname>Pagel</surname><given-names>Judith-Irina</given-names></name><address><email>judith.pagel@med.uni-muenchen.de</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hulde</surname><given-names>Nikolai</given-names></name><address><email>nikolai.hulde@med.uni-muenchen.de</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kammerer</surname><given-names>Tobias</given-names></name><address><email>tobias.kammerer@med.uni-muenchen.de</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Schwarz</surname><given-names>Michaela</given-names></name><address><email>schwarz@chkmb.de</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Chappell</surname><given-names>Daniel</given-names></name><address><email>daniel.chappell@med.uni-muenchen.de</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Burges</surname><given-names>Alexander</given-names></name><address><email>alexander.burges@med.uni-muenchen.de</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Hofmann-Kiefer</surname><given-names>Klaus</given-names></name><address><email>klaus.hofmann-kiefer@med.uni-muenchen.de</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rehm</surname><given-names>Markus</given-names></name><address><email>markus.rehm@med.uni-muenchen.de</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0477 2585</institution-id><institution-id institution-id-type="GRID">grid.411095.8</institution-id><institution>Department of Anaesthesiology, </institution><institution>Hospital of the University of Munich LMU, </institution></institution-wrap>Marchioninistr. 15, 81377 Munich, Germany </aff><aff id="Aff2"><label>2</label>Department of Anaesthesiology, Surgical Clinic of Munich-Bogenhausen, Munich, Germany </aff><aff id="Aff3"><label>3</label>Department of Gynaecology, Hospital of the University of Munich, LMU, Munich, Germany </aff></contrib-group><pub-date pub-type="epub"><day>10</day><month>7</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>10</day><month>7</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>18</volume><elocation-id>313</elocation-id><history><date date-type="received"><day>1</day><month>7</month><year>2016</year></date><date date-type="accepted"><day>13</day><month>6</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">This study aims to investigate the effects of a modified, balanced crystalloid including phosphate in a perioperative setting in order to maintain a stable electrolyte and acid-base homeostasis in the patient.</p></sec><sec><title>Methods/design</title><p id="Par2">This is a single-centre, open-label, randomized controlled trial involving two parallel groups of female patients comparing a perioperative infusion regime with sodium glycerophosphate and Jonosteril&#x000ae; (treatment group) or Jonosteril&#x000ae; (comparator) alone. The primary endpoint is to maintain a stable concentration of weak acids [A<sup>-</sup>] according to the Stewart approach of acid-base balance. Secondary endpoints are measurement of serum phosphate levels, other acid-base parameters such as the strong ion difference (SID), the onset and severity of postoperative nausea and vomiting (PONV), electrolyte levels and their excretion in the urine, monitoring of renal function and glycocalyx components, haemodynamics, amounts of catecholamines and other vasopressors used and the safety of the infusion regime.</p></sec><sec><title>Discussion</title><p id="Par3">Perioperative fluid replacement with the use of currently available crystalloid preparations still fail to maintain a stable acid-base balance and experts agree that common balanced solutions are still not ideal. This study aims to investigate the effectivity and safety of a new crystalloid solution by adding sodium glycerophosphate to a standardized crystalloid preparation in order to maintain a balanced perioperative acid-base homeostasis.</p></sec><sec><title>Trial registration</title><p id="Par4">EudraCT number <ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=PALANCE">201002422520</ext-link>. Registered on 30 November 2010.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s13063-017-2051-z) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Phosphate</kwd><kwd>Fluid replacement therapy</kwd><kwd>Weak acids [A<sup>-</sup>]</kwd><kwd>Stewart concept</kwd><kwd>Acid-base balance</kwd></kwd-group><funding-group><award-group><funding-source><institution>Fresenius Kabi (DE)</institution></funding-source><award-id>not applicable</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p id="Par25">The increasing importance of an adequately balanced crystalloid in terms of outcome has been shown by a range of review articles [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref>]. Current studies target to find the &#x0201c;ideal physiologic&#x0201d; crystalloid preparation, resembling plasma concentrations, maintaining electrolyte concentrations within normal range and stabilizing acid-base balance. In the beginning of the 1990s it was shown that the (excessive) administration of isotonic saline resulted in an acid-base dysbalance, a hyperchloraemic acidosis [<xref ref-type="bibr" rid="CR5">5</xref>] that can effectively mask perfusion deficits or result in inadequate therapeutic interventions if this condition is mistaken as tissue hypoxia [<xref ref-type="bibr" rid="CR6">6</xref>]. Furthermore, we now know that a perioperative hyperchloraemic acidosis induced by administration of saline results in a reduction of renal perfusion and/or urinary excretion [<xref ref-type="bibr" rid="CR7">7</xref>] as well as in a higher incidence of postoperative nausea and vomiting (PONV) morbidity and mortality [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>]. Imbalances in acid-base chemistry can be described with the help of (1) the descriptive Henderson-Hasselbalch equation [<xref ref-type="bibr" rid="CR12">12</xref>], where the blood pH is related to the bicarbonate buffer system, (2) a semiquantitative method using the later introduced concepts of base excess (BE) [<xref ref-type="bibr" rid="CR13">13</xref>] and anion gap (AG) [<xref ref-type="bibr" rid="CR14">14</xref>] as computable factors and (3) the quantitative physicochemical approach by Peter Stewart, which has been intensively discussed in the 1990s but now has been mostly accepted to be the &#x0201c;gold standard&#x0201d; [<xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR17">17</xref>]. The advantage of Stewart&#x02019;s concept is its quantitative analytical approach that permits one to diagnose and differentiate between specific forms of acid-base disturbances that conventional methods have not been able to describe before [<xref ref-type="bibr" rid="CR18">18</xref>].</p><p id="Par26">Stewart based his model on three principles: (1) the sum of all positive charges equals the sum of all negative charges (principle of electroneutrality), (2) the dissociation equilibria of all incompletely dissociated substances must always be satisfied and (3) the total mass of a non-completely dissociated substance can be calculated by summarizing the amount of dissociated and non-dissociated forms. Three components comply to these principles at all times: (1) H<sub>2</sub>O in its dissociated form [H<sup>+</sup>] and [OH<sup>&#x02212;</sup>] (however, the plasma concentration of these ions is extremely low (approximately 10&#x02013;7&#x000a0;mmol/l)), (2) strong ions, such as electrolytes ([Na<sup>+</sup>], [K<sup>+</sup>], [Cl<sup>&#x02212;</sup>], [Ca<sup>2+</sup>], [Mg<sup>2+</sup>] and lactate, which are found nearly completely dissociated and can, therefore, hardly react with other substances in the human body, and (3) weak (= incompletely dissociated) substances comprised of acid-base pairs (carbonic acid/carbon dioxide, NH<sub>3</sub>/NH<sub>4</sub>
<sup>+</sup>) as well as non-volatile plasma proteins and phosphate [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Stewart rigorously distinguished between three <italic>dependent variables</italic> the pH and the concentration of hydrogen ions [H<sup>+</sup>] and bicarbonate [Bic<sup>&#x02212;</sup>] that can only passively respond to alterations determined entirely by three <italic>independent variables</italic>, the carbon dioxide partial pressure (paCO<sub>2</sub>), the weak acids [A<sup>&#x02212;</sup>] (former [A<sub>TOT</sub>]) and the strong ion difference (SID, see below). Stewart also employed the Henderson-Hasselbalch equation to relate respiratory acidosis/alkalosis to changes of the paCO<sub>2</sub>; however, according to his model, a metabolic acidosis/alkalosis cannot be explained with it [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Contemplating the other two independent variables, Stewart proposed that electrolytes, as well as albumin and phosphate, can shift the pH; an entirely new perspective. Currently, there are a couple of formulas proposed to calculate the SID. For the present study we will use the following formulas for [A<sup>&#x02212;</sup>] and the SID published by Figge et al. [<xref ref-type="bibr" rid="CR19">19</xref>]:<disp-formula id="Equ1"><label>1</label><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \mathrm{S}\mathrm{I}\mathrm{D}=\left[{\mathrm{Na}}^{+}\right]+\left[{\mathrm{K}}^{+}\right]-\left(\left[{\mathrm{Cl}}^{-}\right]+\left[{\mathrm{Lac}}^{-}\right]\right) $$\end{document}</tex-math><mml:math id="M2" display="block"><mml:mrow><mml:mi mathvariant="normal">S</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">I</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">D</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:msup><mml:mrow><mml:mrow><mml:mi mathvariant="normal">N</mml:mi><mml:mi mathvariant="normal">a</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msup><mml:mo>]</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:msup><mml:mrow><mml:mrow><mml:mi mathvariant="normal">K</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msup><mml:mo>]</mml:mo></mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:msup><mml:mrow><mml:mrow><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mo>&#x02212;</mml:mo></mml:mrow></mml:msup><mml:mo>]</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:msup><mml:mrow><mml:mrow><mml:mi mathvariant="normal">L</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">c</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mo>&#x02212;</mml:mo></mml:mrow></mml:msup><mml:mo>]</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:math><graphic xlink:href="13063_2017_2051_Article_Equ1.gif" position="anchor"/></alternatives></disp-formula>
<disp-formula id="Equ2"><label>2</label><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \left[{\mathrm{A}}^{-}\right]=\left[\mathrm{Alb}\times \left(0.123\times \mathrm{pH}-0.631\right)\right]+\left[\mathrm{Pix}\left(0.309\times \mathrm{pH}-0.469\right)\right] $$\end{document}</tex-math><mml:math id="M4" display="block"><mml:mrow><mml:mo>[</mml:mo><mml:msup><mml:mrow><mml:mrow><mml:mi mathvariant="normal">A</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mo>&#x02212;</mml:mo></mml:mrow></mml:msup><mml:mo>]</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">b</mml:mi></mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mn>0.123</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:mrow><mml:mi mathvariant="normal">p</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">H</mml:mi></mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mn>0.631</mml:mn><mml:mo>)</mml:mo></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">x</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mn>0.309</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:mrow><mml:mi mathvariant="normal">p</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">H</mml:mi></mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mn>0.469</mml:mn><mml:mo>)</mml:mo></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:math><graphic xlink:href="13063_2017_2051_Article_Equ2.gif" position="anchor"/></alternatives></disp-formula>
</p><p id="Par27">where [Na<sup>+</sup>]&#x02009;=&#x02009;sodium, [K<sup>+</sup>]&#x02009;=&#x02009;potassium, [Cl<sup>&#x02212;</sup>]&#x02009;=&#x02009;chloride, [Lac<sup>&#x02212;</sup>]&#x02009;=&#x02009;lactate, [Alb]&#x02009;=&#x02009;albumin in g/L and</p><p id="Par28">[Pi]&#x02009;=&#x02009;phosphate in mmol/l concentrations in the serum.</p><p id="Par29">Normal values for the SID and [A<sup>&#x02212;</sup>] in human plasma at a pH of 7.4 lie around 40&#x000a0;meq/l and 15&#x000a0;meq/l, respectively. The unit milliequivalents per litre (meq/l) refers to the electric charge (e.g., 2&#x000a0;mmol [Na<sup>+</sup>]&#x02009;=&#x02009;2&#x000a0;meq). Therefore, a normal SID can be calculated with formula (1) as follows:</p><p id="Par30">SID&#x02009;=&#x02009;(142&#x000a0;meq/l)&#x02009;+&#x02009;(4&#x000a0;meq/l) &#x02013; (105&#x000a0;meq/l) &#x02013; (1&#x000a0;meq/l)&#x02009;=&#x02009;40&#x000a0;meq/l.</p><p id="Par31">The following relationship between SID, [A<sup>&#x02212;</sup>] and the pH has been established:<disp-formula id="Equa"><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \mathrm{S}\mathrm{I}\mathrm{D}\uparrow \mathrm{and}/\mathrm{or}\left[{\mathrm{A}}^{-}\right]\downarrow \kern2.75em \to \kern2.5em \mathrm{Alkalosis} $$\end{document}</tex-math><mml:math id="M6"><mml:mi mathvariant="normal">S</mml:mi><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mo>&#x02191;</mml:mo><mml:mi mathvariant="normal">and</mml:mi><mml:mo stretchy="true">/</mml:mo><mml:mi mathvariant="normal">or</mml:mi><mml:mfenced close="]" open="["><mml:msup><mml:mi mathvariant="normal">A</mml:mi><mml:mo>&#x02212;</mml:mo></mml:msup></mml:mfenced><mml:mo>&#x02193;</mml:mo><mml:mspace width="2.75em"/><mml:mo>&#x02192;</mml:mo><mml:mspace width="2.5em"/><mml:mi mathvariant="normal">Alkalosis</mml:mi></mml:math><graphic xlink:href="13063_2017_2051_Article_Equa.gif" position="anchor"/></alternatives></disp-formula>
<disp-formula id="Equb"><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \mathrm{S}\mathrm{I}\mathrm{D}\downarrow \mathrm{and}/\mathrm{or}\left[{\mathrm{A}}^{-}\right]\uparrow \kern2.75em \to \kern2.5em \mathrm{Acidosis} $$\end{document}</tex-math><mml:math id="M8"><mml:mi mathvariant="normal">S</mml:mi><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mo>&#x02193;</mml:mo><mml:mi mathvariant="normal">and</mml:mi><mml:mo stretchy="true">/</mml:mo><mml:mi mathvariant="normal">or</mml:mi><mml:mfenced close="]" open="["><mml:msup><mml:mi mathvariant="normal">A</mml:mi><mml:mo>&#x02212;</mml:mo></mml:msup></mml:mfenced><mml:mo>&#x02191;</mml:mo><mml:mspace width="2.75em"/><mml:mo>&#x02192;</mml:mo><mml:mspace width="2.5em"/><mml:mi mathvariant="normal">Acidosis</mml:mi></mml:math><graphic xlink:href="13063_2017_2051_Article_Equb.gif" position="anchor"/></alternatives></disp-formula>
</p><p id="Par32">Applying this concept, it becomes evident that an increase in chloride lowers the SID, leading to the previously mentioned hyperchloraemic acidosis and that hypoalbuminemia lowers [A<sup>&#x02212;</sup>], shifting the balance towards an alkalotic state. These new insights into the cause of different types of metabolic acid-base disorders comprise the novelty and ingenuity of Stewart&#x02019;s concept.</p><sec id="Sec2"><title>Trial rationale and hypothesis</title><p id="Par33">Many crystalloid preparations contain a non-physiologic concentration of electrolytes. Although the unprotected term &#x0201c;balanced&#x0201d; is widely used for different crystalloid preparations by authors and manufacturers, there is currently no perfectly balanced preparation available. NaCl 0.9%&#x000a0;w/v (isotonic saline) solution consists of 154&#x000a0;mmol/l (=154&#x000a0;meq/l) [Na<sup>+</sup>] and 154&#x000a0;mmol/l (= 154&#x000a0;meq/l) [Cl<sup>&#x02212;</sup>]. The SID of 0.9% isotonic saline is, therefore, 0&#x000a0;meq/l. The administration of large amounts of saline will dilute the patient&#x02019;s former physiologic SID resulting in acidosis. Ringer&#x02019;s lactate and other balanced solutions show a SID of 27&#x02009;&#x02212;&#x02009;36&#x000a0;meq/l which is much closer to physiologic values [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. This was acquired by replacing a certain amount of chloride with a metabolizable anion like lactate, acetate or maleate. Though better balanced than 0.9% isotonic saline, these solutions neither contain albumin nor phosphate and, thus, cannot prevent the dilution of [A<sup>&#x02212;</sup>] and hence the possible onset of an alkalotic state if infused in humans. As a consequence, they are not really &#x0201c;balanced&#x0201d; in the sense of Stewart&#x02019;s approach. The key aspect of the planned investigation is to test the applicability of a new phosphate-balanced crystalloid preparation based on Stewart&#x02019;s concept of acid-base. The novelty of this study is the fact that sodium glycerophosphate is administered in patients undergoing major abdominal surgery not to replenish low phosphate levels as a therapeutic approach, but to stabilize them pre-emptively.</p><p id="Par34">We hypothesize that the patients&#x02019; [A<sup>&#x02212;</sup>] levels can be stabilized when adding phosphate to a standard crystalloid. Additionally, in contrast to the control group, perioperative hypophosphatemia can be avoided by the supplementation of phosphate. It will, therefore, be tested whether Jonosteril&#x000ae; (Fresenius Kabi AG, Bad Homburg, Germany, see below) (investigational medical product 1 (IMP1)) in combination with sodium glycerophosphate (Fresenius Kabi AG, Bad Homburg, Germany) (IMP2)) is able to maintain a more constant acid-base balance in the patient compared to Jonosteril&#x000ae; alone. Additionally, a reduction of PONV is possible. Both preparations are approved substances and frequently administered during daily clinical routine.</p></sec><sec id="Sec3"><title>Jonosteril&#x000ae;</title><p id="Par35">The crystalloid Jonosteril&#x000ae; is routinely administered for perioperative fluid therapy at the authors&#x02019; institution. It contains electrolytes in physiologic concentrations as well as acetate (Na<sup>+</sup> 137&#x000a0;mmol/l, K<sup>+</sup> 4&#x000a0;mmol/l, Ca<sup>2+</sup> 1.65&#x000a0;mmol/l, Mg<sup>2+</sup> 1.25&#x000a0;mmol/l, Cl<sup>&#x02212;</sup> 110&#x000a0;mmol/l, acetate<sup>&#x02212;</sup> 36.8&#x000a0;mmol/l); however, it does not carry albumin or phosphate. As such, this crystalloid is capable to maintain a SID within normal range; it will, however, not be able to prevent a decrease of [A<sup>&#x02212;</sup>] due to the occurring dilution [<xref ref-type="bibr" rid="CR22">22</xref>]. The latter and the decrease of albumin and phosphate will most likely result in hypoalbuminemia, shifting the system towards alkalosis. Contraindications for the use of Jonosteril&#x000ae; are any form of hypersensitivity or allergy to the components of the crystalloid as well as hyperhidratation and hyperkalaemia, according to the manufacturer. Only the crystalloid Jonosteril&#x000ae; will be tested in this study, further studies will be necessary to evaluate the applicability also for other crystalloid preparations.</p></sec><sec id="Sec4"><title>Sodium glycerophosphate</title><p id="Par36">Sodium glycerophosphate (Fresenius Kabi AG, Bad Homburg, Germany; concentration 1&#x000a0;mmol/ml, ATC-Code: B05XA) is an electrolyte supplement approved and routinely administered for the parenteral treatment of hypophosphatemia especially on intensive care units (ICUs). Phosphate is usually not routinely measured during surgical procedures and is, therefore, not substituted. Accordingly, a hypophosphatemia occurs frequently with an incidence of between 44.8% [<xref ref-type="bibr" rid="CR23">23</xref>] and 67% [<xref ref-type="bibr" rid="CR24">24</xref>] and remains undetected, although the unfavourable effects in terms of post-aggression metabolism are well known. The ATP- dependent metabolism strongly relies on phosphate as a substrate, especially during the postoperative phase of major cardiac and abdominal surgery [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. This leads to a high turnover of phosphate and requires parenteral substitution. Therefore, an intraoperative substitution of phosphate seems reasonable and indicated. It has been shown that an early perioperative substitution of phosphate during liver surgery had a protective effect in terms of cardiorespiratory complication and is, therefore, recommended [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. Prior to inclusion, all patients will be evaluated regarding contraindications for the use of sodium glycerophosphate (existing chronic kidney disease or renal failure, hyperphosphatemia, hypernatremia or allergic disposition towards sodium glycerophosphate or its components). If none of the above can be detected, the parenteral application of sodium glycerophosphate is uncritical. By contrast to the dosage given on ICUs [<xref ref-type="bibr" rid="CR29">29</xref>] or according to an estimated basic daily demand of 0.2&#x02013;0.5&#x000a0;mmol/kg bodyweight (according to the summary of product characteristics) the amount of phosphate given during this trial is low. The maximum infusion rate is 20&#x000a0;mmol phosphate per hour according to the manufacturer and will not be reached. It is expected that during the observation period and due to the substitution, serum phosphate levels will rise around 0.5&#x000a0;mmol/l [<xref ref-type="bibr" rid="CR22">22</xref>] which will be controlled every 30&#x000a0;min. Since the substituted phosphate gets rapidly metabolized and excess phosphate is excreted in the urine, a severe hyperphosphatemia is not expected [<xref ref-type="bibr" rid="CR30">30</xref>]. Before initiation of the trial, it was confirmed that Jonosteril&#x000ae; and sodium glycerophosphate are compatible for the intended use. Phosphate will be added to Jonosteril&#x000ae; immediately prior to the application to avoid any potential risk of infection.</p></sec></sec><sec id="Sec5"><title>Outcome measures</title><sec id="Sec6"><title>Primary objective</title><p id="Par37">The primary objective is to compare two infusion therapy regimes, Jonosteril&#x000ae;&#x02009;+&#x02009;Sodium glycerophosphate (IMP1/IMP2) versus Jonosteril&#x000ae; (IMP1) alone, with the aim to demonstrate superiority of IMP1/IMP2 over IMP1 due to a more stable value of [A<sup>&#x02212;</sup>] during the observation period of 120&#x000a0;min after the initiation of general anaesthesia.</p></sec><sec id="Sec7"><title>Primary endpoint</title><p id="Par38">The primary endpoint is the calculation of [A<sup>&#x02212;</sup>] in mmol/l according to the Stewart approach of acid-base balance (using equation (2); numerical deviation from reference baseline value around 15&#x000a0;meq/l) and takes place every 30&#x000a0;min over 120&#x000a0;min (time points T1&#x02009;&#x02212;&#x02009;T5).</p></sec><sec id="Sec8"><title>Secondary objectives</title><p id="Par39">The secondary objectives of the trial are the influence of the distinct infusion therapy regimens on other acid-base parameters, on the onset of PONV, laboratory chemical parameters like electrolytes and their excretion in the urine, as well as hemodynamic stability, monitoring of the vascular barrier (shedding of the glycocalyx), the the use of vasopressors and the safety of the crystalloid preparation in this setting.</p><p id="Par40">Secondary endpoints of the trial are:<list list-type="bullet"><list-item><p id="Par41">Serum phosphate levels (ionized in mmol/l, non-ionized in mg/dl, continuous measure from baseline T0 and serial blood draws over a 120-min time frame T1&#x02009;&#x02212;&#x02009;T5)</p></list-item><list-item><p id="Par42">Acid-base parameters: pH (numerical), paCO<sub>2</sub> (mmHg), HCO<sub>3</sub>
<sup>&#x02212;</sup> (mmol/l), BE (mmol/l), anion gap (mmol/l); (continuous measure from baseline T0 and serial blood draws over a 120-min time frame T1&#x02009;&#x02212;&#x02009;T5)</p></list-item><list-item><p id="Par43">Apparent SID and effective SID (both in mmol/l), Strong Ion Gap (mmol/l), albumin, lactate (ionized in mmol/l, non-ionized in mg/dl, continuous measure from baseline measures T0 and serial blood draws over a 120-min time frame T1&#x02009;&#x02212;&#x02009;T5) serum and urine analysis of electrolytes (osmolality in mosmol/l; all other in mmol/l, continuous measure on T6, change from baseline T0)</p></list-item><list-item><p id="Par44">Documentation and analysis of mean arterial blood pressure (MAP) in mmHg, heart frequency in min<sup>-1</sup>, demand of vasopressors (norepinephrine dose in mg/h), stroke volume variation (SVV) in %, central venous pressure (CVP) in mmHg and cardiac output in ml/min (continuous measure from baseline T0 and serial blood draws over a 120-min time frame T1&#x02013;T5)</p></list-item><list-item><p id="Par45">Assessment of serum creatinine (mg/dl) and urea (mg/dl) as well as calculation of the glomerular filtration rate (ml/min) and creatinine clearance (C<sub>cr</sub>) in ml/min according to the Cockroft-Gault equation [<xref ref-type="bibr" rid="CR31">31</xref>] as continuous measure on two blood draws at T0 and T6, change from baseline T0)</p></list-item></list>
<disp-formula id="Equc"><alternatives><tex-math id="M9">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ {\mathrm{C}}_{\mathrm{cr}}=\frac{\left(140-\mathrm{Age}\ \mathrm{in}\ \mathrm{years}\right) \times \mathrm{Mass}\ \left(\mathrm{in}\ \mathrm{kg}\right) \times \left[0.85\ \mathrm{if}\ \mathrm{female}\right]}{72 \times \mathrm{Serum}\ \mathrm{Creatinine}\ \left(\mathrm{in}\ \mathrm{mg}/ dl\right)} $$\end{document}</tex-math><mml:math id="M10"><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mn>140</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mi mathvariant="normal">Age</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">in</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">years</mml:mi></mml:mrow></mml:mfenced><mml:mspace width="0.25em"/><mml:mo>&#x000d7;</mml:mo><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">Mass</mml:mi><mml:mspace width="0.25em"/><mml:mfenced close=")" open="("><mml:mrow><mml:mi mathvariant="normal">in</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">kg</mml:mi></mml:mrow></mml:mfenced><mml:mspace width="0.25em"/><mml:mo>&#x000d7;</mml:mo><mml:mspace width="0.25em"/><mml:mfenced close="]" open="["><mml:mrow><mml:mn>0.85</mml:mn><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">if</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">female</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>72</mml:mn><mml:mspace width="0.25em"/><mml:mo>&#x000d7;</mml:mo><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">Serum</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">Creatinine</mml:mi><mml:mspace width="0.25em"/><mml:mfenced close=")" open="("><mml:mrow><mml:mi mathvariant="normal">in</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">mg</mml:mi><mml:mo stretchy="true">/</mml:mo><mml:mi mathvariant="italic">dl</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mfrac></mml:math><graphic xlink:href="13063_2017_2051_Article_Equc.gif" position="anchor"/></alternatives></disp-formula>
<list list-type="bullet"><list-item><p id="Par46">Monitoring of the integrity of the vascular barrier function via detection of hyaluronic acid and syndecan-1 (shedding of glycocalyx components) (in ng/ml, continuous measure from baseline T0 and serial blood draws over a 120-min time frame T1&#x02013;T5)</p></list-item><list-item><p id="Par47">Evaluation and documentation of postoperative nausea and vomiting (descriptive evaluation on day of surgery until postoperative day 3, patients&#x02019; account and anaesthesia protocol of surgery, dichotomic measure: yes/no)</p></list-item><list-item><p id="Par48">Onset frequency and intensity of unexpected events: UE/ SUE and SUSARs (critical assessment on day of surgery T1&#x02013;T5 until postoperative day 3, onset: date, severity score 1&#x02013;3: mild, moderate, severe, according to detailed injury reporting plan)</p></list-item><list-item><p id="Par49">Necessity of renal replacement therapy (descriptive evaluation, after surgery until postoperative day-3 dichotomic measure: yes/no)</p></list-item></list>
</p></sec></sec><sec id="Sec9"><title>Methods/design</title><p id="Par50">This is a single-centre, phase II clinical trial in patients undergoing major abdominal surgery (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). The study follows a prospective, controlled and open design. Initially, the study will begin with a pilot phase of six patients followed by a randomization phase. An overview of the patients&#x02019; schedule of activities according to the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) figure is provided in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>.<fig id="Fig1"><label>Fig. 1</label><caption><p>Participant flow diagram showing the organizational structure and different study groups of PALANCE</p></caption><graphic xlink:href="13063_2017_2051_Fig1_HTML" id="MO1"/></fig>
<fig id="Fig2"><label>Fig. 2</label><caption><p>Patient schedule of activities according to the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) figure. <italic>SID</italic> Strong Ion Difference, <italic>SUEs</italic> serious unexpected events, <italic>SUSARS</italic> severe unexpected serious adverse event, <italic>UE</italic> unexpected events, <italic>UO</italic> urinary output</p></caption><graphic xlink:href="13063_2017_2051_Fig2_HTML" id="MO2"/></fig>
</p><sec id="Sec10"><title>Pilot phase</title><p id="Par51">The first six patients will receive Jonosteril&#x000ae; together with sodium glycerophosphate (IMP1/IMP2 protocol) in concentrations ranging from 1 to 6&#x000a0;mmol/l (Na<sup>+</sup>: 139&#x02013;149&#x000a0;mmol/l) to evaluate the most suitable concentration for the following randomization phase. We will test a concentration of 4&#x000a0;mmol/l phosphate (= 2&#x000a0;ml sodium glycerophosphate per 500&#x000a0;ml Jonosteril&#x000ae;) initially. This solution will contain 145&#x000a0;mmol/l sodium. Repeated measurements of serum phosphate levels will shed light on the efficacy of the measure. In the case that serum phosphate levels do not remain stable within the normal range, we will gradually adapt the dose until stable levels are achieved. Patients will not receive a concentration higher than 6&#x000a0;mmol/l since then the sodium levels would surpass the maximum threshold value.</p></sec><sec id="Sec11"><title>Randomization phase</title><p id="Par52">After the pilot phase, in which the most suitable phosphate concentration is determined, a total of 42 patients, 21 per group, will be allocated to one of the two study arms by randomization:<list list-type="bullet"><list-item><p id="Par53">Jonosteril&#x000ae; and sodium glycerophosphate (IMP1/IMP2) (treatment group)</p></list-item><list-item><p id="Par54">Jonosteril&#x000ae; (IMP1) (control group)</p></list-item></list>
</p><p id="Par55">All patients will receive the study medication according to their allocation over 120&#x000a0;min after the initiation of general anaesthesia in a maximum dose of 30&#x000a0;ml per ideal bodyweight (IBW&#x02009;=&#x02009;height (in cm)&#x02009;&#x02212;&#x02009;100) per hour for losses due to insensible perspiration, urinary output and extracellular deficits due to the fasting state as well as five times the estimated blood loss [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. The rationale for the use of the amount of fluids is based on previous studies and the demand-oriented current clinical practice. This is in concordance with previous studies using similar regimes. The recruited patients have a higher fluid demand [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Hofmann-Kiefer et al. showed that a maximum of 30&#x000a0;ml/kg/bodyweight was necessary to keep patients hemodynamically stable and distinct acid-base alterations were described. Over the time course of 120&#x000a0;min, the patients likely suffer from a blood loss of 1000&#x000a0;ml or more. According to current clinical practice, a blood loss should be replaced in a ratio of 4&#x02013;5:1 with crystalloids [<xref ref-type="bibr" rid="CR33">33</xref>]. Taken together, our approach using 30&#x000a0;ml/kg/ideal bodyweight seems reasonable for this patient cohort. Measurements will take place every 30&#x000a0;min: baseline (T1), 30&#x000a0;min (T2), 60&#x000a0;min (T3), 90&#x000a0;min (T4) and 120&#x000a0;min (T5) and parameters will be documented by the investigators in the Case Report Forms (CRF) of each participant. An overview of the parameters assessed in this study and their respective time points is provided in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Parameters measured at the distinct time points</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Measurement</th><th>Time point</th></tr></thead><tbody><tr><td colspan="2">Haemodynamic values</td></tr><tr><td>&#x02003;Norepinephrine dose (mg/h)</td><td>T1&#x02013;T5</td></tr><tr><td>&#x02003;Heart rate (min<sup>-1</sup>)</td><td>T1&#x02013;T5</td></tr><tr><td>&#x02003;Systolic blood pressure (mmHg)</td><td>T1&#x02013;T5</td></tr><tr><td>&#x02003;Diastolic blood pressure (mmHg)</td><td>T1&#x02013;T5</td></tr><tr><td>&#x02003;Central venous pressure (mmHg)</td><td>T1&#x02013;T5</td></tr><tr><td>&#x02003;Stroke volume variation (%)</td><td>T1&#x02013;T5</td></tr><tr><td>&#x02003;Cardiac output (ml/min)</td><td>T1&#x02013;T5</td></tr><tr><td>&#x02003;Blood loss (ml)</td><td>T1&#x02013;T5</td></tr><tr><td>&#x02003;Haemoglobin (g/dl)</td><td>T1&#x02013;T5</td></tr><tr><td>&#x02003;Haematocrit (%)</td><td>T1&#x02013;T5</td></tr><tr><td>&#x02003;Urine volume (ml)</td><td>T1&#x02013;T5</td></tr><tr><td>&#x02003;Crystalloid administered (ml)</td><td>T1&#x02013;T5</td></tr><tr><td colspan="2">Serum electrolytes</td></tr><tr><td>&#x02003;[PO<sub>4</sub>
<sup>3-</sup>] ionized (mmol/l)</td><td>T0&#x02013;T5</td></tr><tr><td>&#x02003;[PO<sub>4</sub>
<sup>3-</sup>] (mg/dl)</td><td>T0&#x02013;T5</td></tr><tr><td>&#x02003;[Na<sup>+</sup>] (mmol/l)</td><td>T1&#x02013;T5</td></tr><tr><td>&#x02003;[K<sup>+</sup>] (mmol/l)</td><td>T1&#x02013;T5</td></tr><tr><td>&#x02003;[Cl<sup>&#x02212;</sup>] (mmol/l)</td><td>T1&#x02013;T5</td></tr><tr><td>&#x02003;[Mg<sup>2+</sup>] (mmol/l)</td><td>T1&#x02013;T5</td></tr><tr><td>&#x02003;[Ca<sup>2+</sup>] (mmol/l)</td><td>T1&#x02013;T5</td></tr><tr><td>&#x02003;Osmolality (mosmol/l)</td><td>T1&#x02013;T5</td></tr><tr><td colspan="2">Renal function</td></tr><tr><td>&#x02003;Serum creatinine (mg/dl)</td><td>T0 and T6</td></tr><tr><td>&#x02003;Serum urea nitrogen (mg/dl)</td><td>T0 and T6</td></tr><tr><td>&#x02003;GFR calculated (ml/min)</td><td>T0 and T6</td></tr><tr><td colspan="2">Acid-base values</td></tr><tr><td>&#x02003;Anion gap (mmol/l)</td><td>T1&#x02013;T5</td></tr><tr><td>&#x02003;HCO3<sup>-</sup> (mmol/l)</td><td>T1&#x02013;T5</td></tr><tr><td>&#x02003;BE (mmol/l)</td><td>T1&#x02013;T5</td></tr><tr><td>&#x02003;pH</td><td>T1&#x02013;T5</td></tr><tr><td>&#x02003;PaCO<sub>2</sub> (mmHg)</td><td>T1&#x02013;T5</td></tr><tr><td colspan="2">Stewart acid-base parameters</td></tr><tr><td>&#x02003;[A<sup>-</sup>] (mmol/l)</td><td>T1&#x02013;T5</td></tr><tr><td>&#x02003;Strong Ion Difference (mmol/l)</td><td>T1&#x02013;T5</td></tr><tr><td>&#x02003;Effective Strong Ion Difference</td><td>T1&#x02013;T5</td></tr><tr><td>&#x02003;Strong Ion Gap (mmol/l)</td><td>T1&#x02013;T5</td></tr><tr><td>&#x02003;Albumin (mg/dl)</td><td>T1&#x02013;T5</td></tr><tr><td>&#x02003;Lactate (mmol/l)</td><td>T1&#x02013;T5</td></tr><tr><td colspan="2">Urine</td></tr><tr><td>&#x02003;[Urinary Na<sup>+</sup>] (mmol/l)</td><td>T1 and T5</td></tr><tr><td>&#x02003;[Urinary K<sup>+</sup>] (mmol/l)</td><td>T1 and T5</td></tr><tr><td>&#x02003;[Urinary Cl<sup>&#x02212;</sup>] (mmol/l)</td><td>T1 and T5</td></tr><tr><td>&#x02003;[Urinary Mg<sup>2+</sup>] (mmol/l)</td><td>T1 and T5</td></tr><tr><td>&#x02003;[Urinary Ca<sup>2+</sup>] (mmol/l)</td><td>T1 and T5</td></tr><tr><td>&#x02003;[Urine osmolality] (mosmol/l)</td><td>T1 and T5</td></tr><tr><td>&#x02003;[Urinary phosphate] (mmol/l)</td><td>T1 and T5</td></tr><tr><td colspan="2">Glycocalyx components</td></tr><tr><td>&#x02003;Syndecan-1</td><td>T1&#x02013;T5</td></tr><tr><td>&#x02003;Hyaluronic acid</td><td>T1&#x02013;T5</td></tr></tbody></table><table-wrap-foot><p>
<italic>BE</italic> base excess, <italic>GFR</italic> glomerular filtration rate</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec12"><title>Anaesthesiologic management and postoperative care</title><p id="Par56">All patients will receive anaesthesiologic management according to the institution&#x02019;s standard. This involves a thoracic epidural anaesthesia in combination with general anaesthesia and the placement of a central venous line and an arterial catheter for haemodynamic monitoring. In case of contraindications to neuroaxial procedures patients will receive general anaesthesia and, postoperatively, patient-controlled analgesia with piritramide. Anaesthesia will be induced with propofol (2&#x000a0;mg/kg), sufentanil (0.4&#x000a0;mg/kg) and rocuronium (0.6&#x000a0;mg/kg) and maintained with propofol and remifentanil or sevoflurane in patients with certain conditions (e.g. cardiopulmonary diseases). The pulmonary ventilation will be standardized in all patients using the volume-controlled mode in order to keep the paCO<sub>2</sub> at 40&#x02009;&#x000b1;&#x02009;3&#x000a0;mmHg as to have as little influence on acid-base balance as possible (controls are performed using blood gas analysis). The epidural anaesthesia will be continued for at least 3&#x000a0;days and will be combined with nonsteroidal anti-inflammatory drugs. Intraoperative hemodynamic monitoring will be performed using a PulsioFlex monitor with ProAQT&#x000ae; sensor (PULSION Medical Systems SE, Germany). The observation period will be 120&#x000a0;min after initiation of anaesthesia although surgery will take longer in most cases. The administration of the study drug, e.g., sodium glycerophosphate, as well as study-specific blood draws, will take place only during the 120&#x000a0;min of the procedure. Afterwards, the anaesthetist responsible for the patient will continue according to clinical standards. All patients will be transferred from the operating room to the ICU for postoperative surveillance and will be visited by in-hospital postoperative pain management service staff daily.</p></sec><sec id="Sec13"><title>Trial population and selection criteria</title><p id="Par57">Patients are identified based on their diagnosis and scheduled surgery at the department of gynaecology. We recruit only female patients who are scheduled for major abdominal surgery, i.e. laparotomy. By routine, these patients will undergo placement of a central venous line and an arterial line. Laparoscopic or transvaginal approaches are not included. We screen eligible patients for study participation according to the predefined inclusion and exclusion criteria and provide information regarding the trial during a pre-operatory orientation interview with one of the investigators of the team. We will obtain informed consents from all participants of the study. In addition to informed consent regarding the participation in the study, the patient will be asked to sign a separate informed consent for the frozen storage and possible use of blood samples for scientific purposes to address comments of reviewers during the publication phase. The latter consent is independent of participation in the study. Patients receive complete information about the trial and enough time to consider participation.</p><sec id="Sec14"><title>Inclusion criteria</title><p id="Par58">Subjects must meet the following inclusion criteria to be eligible for enrolment:<list list-type="bullet"><list-item><p id="Par59">Female patients (ASA Classification I&#x02013;III) who are scheduled for a major abdominal surgical procedure under general anaesthesia with routinely planned placement of a central venous and an arterial catheter and who have given written informed consent</p></list-item><list-item><p id="Par60">Age &#x02265;18&#x000a0;years</p></list-item></list>
</p></sec><sec id="Sec15"><title>Exclusion criteria</title><p id="Par61">Subjects showing the following exclusion criteria cannot be included in the trial:<list list-type="bullet"><list-item><p id="Par62">Participation in another clinical trial</p></list-item><list-item><p id="Par63">Patients who are not personally able to give their informed consent</p></list-item><list-item><p id="Par64">Patients at a childbearing age without using contraceptives</p></list-item><list-item><p id="Par65">Acute or chronic renal failure (glomerular filtration rate &#x0003c;60&#x000a0;ml/min)</p></list-item><list-item><p id="Par66">Patients suffering from an acid-base-disturbance (i.e. severe acidosis)</p></list-item><list-item><p id="Par67">Patients suffering from acid-base disturbances caused by SIRS or sepsis</p></list-item><list-item><p id="Par68">Pregnancy or lactation period (pregnancy testing will be executed at least 1&#x000a0;day prior to the surgical procedure)</p></list-item><list-item><p id="Par69">Oedema, hypertonic dehydratation, hyperhidratation</p></list-item><list-item><p id="Par70">Hyperphosphata emia, hypernatraemia, hypocalcaemia (according to the standard normal laboratory values of the authors&#x02019; institution)</p></list-item><list-item><p id="Par71">A known hypersensitivity against the test drugs and/or their components</p></list-item><list-item><p id="Par72">A known history or active abuse of alcohol and/or drugs</p></list-item></list>
</p></sec></sec><sec id="Sec16"><title>Randomization</title><p id="Par73">INPADS GmbH performs the allocation of patients to one of the two study arms using simple, balanced randomization via random numbers. A computer-generated number between 0 and 1 is subsequently analysed as to whether it lies above 0.5 (allocation to IMP1) or below 0.5 (allocation to IMP1 and IMP2 combined). The randomization procedure is executed for all patients after the pilot phase undergo the randomization procedure and a list is generated prior to first patient&#x02019;s first visit (FPFV).</p></sec><sec id="Sec17"><title>Statistical evaluation</title><sec id="Sec18"><title>Power considerations</title><p id="Par74">This study aims to show that [A<sup>&#x02212;</sup>] can be stabilized by applying IMP1/IMP2 in a combined approach. In a previous investigation of our group, [A<sup>&#x02212;</sup>] was reduced by 2.67&#x02009;&#x000b1;&#x02009;2.4&#x000a0;mmol/l in patients who had received 4000&#x000a0;ml of Jonosteril&#x000ae; over 120&#x000a0;min [<xref ref-type="bibr" rid="CR22">22</xref>]. We expect that we can counteract the decrease in [A<sup>&#x02212;</sup>] up to 60% when using the IMP1/IMP2 protocol. This will presumably result in an average difference in [A<sup>&#x02212;</sup>] of 1.602&#x000a0;mmol/l in the treatment group. Furthermore, we assume that [A<sup>&#x02212;</sup>] will be more stable over all time points. As a consequence, the range of [A<sup>&#x02212;</sup>] will be lower in the treatment compared to the control group. Therefore, we expect that the standard deviation will rather be 1.8&#x000a0;mmol/l than 2.4&#x000a0;mmol/l (estimated reduction of 30%) [<xref ref-type="bibr" rid="CR22">22</xref>].</p></sec><sec id="Sec19"><title>Sample size calculation</title><p id="Par75">We calculated the sample size using the statistic software SAS (SAS Institute GmbH, Heidelberg, Germany). This study has an explorative character and is supposed to deliver first-ever data. There is currently no comparative data available for the medication group or time intervals considered. For the control group regimen, there is data available from a previous study [<xref ref-type="bibr" rid="CR22">22</xref>] for two time points (60&#x000a0;min and 120&#x000a0;min after exposure). Therefore, we considered the deviation of [A<sup>&#x02212;</sup>] at the time point T5 (120&#x000a0;min) compared to baseline T1 (0&#x000a0;min) applying a <italic>t</italic> test. We expect normally distributed data since the control group data derived from the previous study showed the same characteristics [<xref ref-type="bibr" rid="CR22">22</xref>]. We set the level of significance to 5% and the power to 80% resulting in 21 patients per group. With the addition of swix patients for the pilot phase, the total number of patients is 48.</p></sec><sec id="Sec20"><title>Analysis procedure</title><p id="Par76">The primary objective of the study is to show that during the observation period of 120&#x000a0;min the mean values of [A<sup>&#x02212;</sup>] display a lower deviation in the treatment group when compared to the control. We will evaluate normal distribution using the Kolmogorov-Smirnov test. To test for differences between two study groups with normally distributed data, a two-sample <italic>t</italic> test will be used. In order to evaluate differences of [A<sup>&#x02212;</sup>] within one study group over time, we will perform a RM-ANOVA with a <italic>t</italic> test for paired samples as post hoc. We will analyse data that does not follow a normal distribution using the Friedman test. Level of significance for all calculations is defined at 5%. We will analyse secondary parameters descriptively and calculate mean, number, minimum, maximum, 1st quartile, 3rd quartile, mean standard error and standard deviation (SD) (method of aggregation: continuous). Further analyses and testing procedures can be defined at a later stage. The primary statistical analysis is based on the &#x0201c;intention-to-treat&#x0201d; principle. Safety data (UE, SUE, SUSARs) will be analysed descriptively in all groups at least every 12&#x000a0;months.</p></sec><sec id="Sec21"><title>Data handling and dropouts</title><p id="Par77">INPADS GmbH will perform data management according to the DEGL and DMP. All patients who drop out will be listed, followed-up and monitored. We will document the reason for dropping out and all data registered until then will be included in the analysis. After inclusion of six patients, we will perform an interim analysis. Although dropouts will be very unlikely, due to the design of the study, we will replace the dropout in the case of such an event. Strategies to improve adherence to protocols involve the participation of an investigator (anaesthesiologist) who is responsible for the trial during the initiation of anaesthesia and in the observation period as well as for the completion of checklists in similar format of the CRF. Since patients are under anaesthesia during the intervention, other strategies, such as patient focused techniques, are not intended.</p></sec></sec><sec id="Sec22"><title>Ethics and Good Clinical Practice</title><p id="Par78">The trial will be conducted in accordance with the Clinical Trials Directive 2001/20/EC of the European Parliament and of the Council, the International Conference on Harmonization guidance regarding Good Clinical Practice (ICH-GCP E6 R1), the relevant national regulations and the Declaration of Helsinki. Monitoring is independent from the sponsor and competing interests. If external auditing is demanded by an authority, it will be independent from investigators and sponsor. Any modifications to the protocol will be, and have been, immediately communicated to all responsible authorities.</p></sec></sec><sec id="Sec23"><title>Discussion</title><p id="Par79">Although there is currently a broad variety of so-called balanced crystalloid preparations available, none of them is ideal and capable of stabilizing the patient&#x02019;s acid-base balance. This is due to the nature of their composition. Stewart&#x02019;s concept of acid-base homeostasis may provide a new approach to improve the daily clinical routine of fluid administration. By administering sodium glycerophosphate pre-emptively, it is hypothesized that stable values of [A<sup>&#x02212;</sup>] can be maintained in patients in the need for larger amounts of fluids due to illness or type of surgery. Furthermore, by supplementing phosphate perioperatively, a frequently occurring hypophosphatemia can be avoided. This trial will increase our knowledge in the applicability of Stewart&#x02019;s concept of acid-base as well as in the field of perioperative fluid substitution, an area that has a broad applicability in medicine and is directly linked to the patients&#x02019; outcome.</p><sec id="Sec24"><title>Trial status</title><p id="Par80">Recruiting: participants are currently being recruited and enrolled.</p></sec><sec id="Sec25"><title>SPIRIT guidelines</title><p id="Par81">The PALANCE study protocol was written in accordance with the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT). A completed SPIRIT Checklist (Additional file <xref rid="MOESM1" ref-type="media">1</xref>) and a SPIRIT figure (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>) has been included in this manuscript.</p></sec></sec></body><back><app-group><app id="App1"><sec id="Sec26"><title>Additional file</title><p id="Par90">
<media position="anchor" xlink:href="13063_2017_2051_MOESM1_ESM.pdf" id="MOESM1"><label>Additional file 1:</label><caption><p>SPIRIT Checklist. (PDF 175&#x000a0;kb)</p></caption></media>
</p></sec></app></app-group><glossary><title>Abbreviations</title><def-list><def-item><term>AE</term><def><p id="Par5">Adverse event</p></def></def-item><def-item><term>ASA</term><def><p id="Par6">American Society of Anaesthesiologists&#x02019; performance status classification system</p></def></def-item><def-item><term>CRF</term><def><p id="Par7">Case Report Form</p></def></def-item><def-item><term>CRO</term><def><p id="Par8">Contract Research organizations</p></def></def-item><def-item><term>DEGL</term><def><p id="Par9">Data entry guideline</p></def></def-item><def-item><term>DMP</term><def><p id="Par10">Data management plan</p></def></def-item><def-item><term>ECG</term><def><p id="Par11">Electrocardiography</p></def></def-item><def-item><term>GFR</term><def><p id="Par12">Glomerular filtration rate</p></def></def-item><def-item><term>Hb</term><def><p id="Par13">Haemoglobin</p></def></def-item><def-item><term>ICU</term><def><p id="Par14">Intensive care unit</p></def></def-item><def-item><term>IMP</term><def><p id="Par15">Investigational medicinal product</p></def></def-item><def-item><term>ITT</term><def><p id="Par16">Intention-to-treat</p></def></def-item><def-item><term>IV</term><def><p id="Par17">Intravenous</p></def></def-item><def-item><term>SAE</term><def><p id="Par18">Serious adverse event</p></def></def-item><def-item><term>SDP</term><def><p id="Par19">Sponsor-delegated person</p></def></def-item><def-item><term>SD</term><def><p id="Par20">Standard deviation</p></def></def-item><def-item><term>SUE</term><def><p id="Par21">Severe unexpected event</p></def></def-item><def-item><term>SUSAR</term><def><p id="Par22">Severe unexpected serious adverse event</p></def></def-item><def-item><term>SVV</term><def><p id="Par23">Stroke volume variation</p></def></def-item><def-item><term>UE</term><def><p id="Par24">Unexpected event</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Electronic supplementary material</bold></p><p>The online version of this article (doi:10.1186/s13063-017-2051-z) contains supplementary material, which is available to authorized users.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We would like to thank Dr. Marion Seybold for her support during the planning phase of the clinical trial. We also thank Christian Mehl and Karola Wittig from INPADS GmbH for the design of the DMP and for their support in data analysis. Furthermore, we thank the in-house clinical staff supporting this trial.</p><sec id="FPar1"><title>Funding</title><p id="Par82">The present trial is an investigator-sponsored trial (IST). Primary sponsor is the University Hospital of the University of Munich, LMU, Marchioninistr. 15, 81377 Munich and the protocol-code of the sponsor is 301110_PALANCE. This report is based on protocol version 1.3, dated 21.01.2015. Secondary sponsor is Fresenius Kabi, Germany. The sponsors had neither a role in the study design nor will they influence data collection, data analysis, data interpretation or writing of the report.</p><p id="Par83">The PALANCE trial was authorized by the Federal Institute for Drugs and Medical Devices (Bundesinstitut f&#x000fc;r Arzneimittel und Medizinprodukte, BfArM), Germany and is registered as 2010-024225-20 (EudraCT number). Results obtained in this trial will be published in an international journal.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p id="Par84">Access to the personal data of participants as well as to the final data set will only be granted to designated trial investigators and team members of contract research organizations (CRO) handling primary data of this trial. Data confidentiality will be respected at all times. Data sharing has not yet been planned.</p></sec><sec id="FPar3"><title>Authors&#x02019; contributions</title><p id="Par85">MR, JIP and MS drafted the study protocol. MR is the main investigator and sponsor delegated person (SDP) of the trial. NH, MR, TK and JIP are responsible for the implementation of the study. AB, KHK and DC are co-investigators. All authors contributed to the design of the trial, critically reviewed and approved the final manuscript.</p></sec><sec id="FPar4"><title>Competing interests</title><p id="Par86">The authors declare that they have no competing interests.</p></sec><sec id="FPar5"><title>Consent for publication</title><p id="Par87">We will obtain written informed consent for publication of the acquired anonymous data from each participant.</p></sec><sec id="FPar6"><title>Ethics approval and consent to participate</title><p id="Par88">The Institutional Review Board of the Ludwig Maximillian&#x02019;s University of Munich approved the study protocol and Consent Forms (reference number 134-13). We will obtain written informed consents from all participants prior to inclusion in the study.</p></sec><sec id="FPar7"><title>Publisher&#x02019;s Note</title><p id="Par89">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holte</surname><given-names>K</given-names></name><name><surname>Kehlet</surname><given-names>H</given-names></name></person-group><article-title>Fluid therapy and surgical outcomes in elective surgery: a need for reassessment in fast-track surgery</article-title><source>J Am Coll Surg</source><year>2006</year><volume>202</volume><issue>6</issue><fpage>971</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1016/j.jamcollsurg.2006.01.003</pub-id><pub-id pub-id-type="pmid">16735213</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacob</surname><given-names>M</given-names></name><name><surname>Chappell</surname><given-names>D</given-names></name><name><surname>Rehm</surname><given-names>M</given-names></name></person-group><article-title>Clinical update: perioperative fluid management</article-title><source>Lancet</source><year>2007</year><volume>369</volume><issue>9578</issue><fpage>1984</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(07)60926-X</pub-id><pub-id pub-id-type="pmid">17574081</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Malley</surname><given-names>CM</given-names></name><name><surname>Frumento</surname><given-names>RJ</given-names></name><name><surname>Hardy</surname><given-names>MA</given-names></name><name><surname>Benvenisty</surname><given-names>AI</given-names></name><name><surname>Brentjens</surname><given-names>TE</given-names></name><name><surname>Mercer</surname><given-names>JS</given-names></name><etal/></person-group><article-title>A randomized, double-blind comparison of lactated Ringer&#x02019;s solution and 0.9% NaCl during renal transplantation</article-title><source>Anesth Analg</source><year>2005</year><volume>100</volume><issue>5</issue><fpage>1518</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1213/01.ANE.0000150939.28904.81</pub-id><pub-id pub-id-type="pmid">15845718</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guidet</surname><given-names>B</given-names></name><name><surname>Soni</surname><given-names>N</given-names></name><name><surname>Della Rocca</surname><given-names>G</given-names></name><name><surname>Kozek</surname><given-names>S</given-names></name><name><surname>Vallet</surname><given-names>B</given-names></name><name><surname>Annane</surname><given-names>D</given-names></name><etal/></person-group><article-title>A balanced view of balanced solutions</article-title><source>Crit Care</source><year>2010</year><volume>14</volume><issue>5</issue><fpage>325</fpage><pub-id pub-id-type="doi">10.1186/cc9230</pub-id><pub-id pub-id-type="pmid">21067552</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McFarlane</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>A</given-names></name></person-group><article-title>A comparison of Plasmalyte 148 and 0.9% saline for intra-operative fluid replacement</article-title><source>Anaesthesia</source><year>1994</year><volume>49</volume><issue>9</issue><fpage>779</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2044.1994.tb04450.x</pub-id><pub-id pub-id-type="pmid">7978133</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brill</surname><given-names>SA</given-names></name><name><surname>Stewart</surname><given-names>TR</given-names></name><name><surname>Brundage</surname><given-names>SI</given-names></name><name><surname>Schreiber</surname><given-names>MA</given-names></name></person-group><article-title>Base deficit does not predict mortality when secondary to hyperchloremic acidosis</article-title><source>Shock</source><year>2002</year><volume>17</volume><issue>6</issue><fpage>459</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1097/00024382-200206000-00003</pub-id><pub-id pub-id-type="pmid">12069180</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chowdhury</surname><given-names>AH</given-names></name><name><surname>Cox</surname><given-names>EF</given-names></name><name><surname>Francis</surname><given-names>ST</given-names></name><name><surname>Lobo</surname><given-names>DN</given-names></name></person-group><article-title>A randomized, controlled, double-blind crossover study on the effects of 2-L infusions of 0.9% saline and plasma-lyte (R) 148 on renal blood flow velocity and renal cortical tissue perfusion in healthy volunteers</article-title><source>Ann Surg</source><year>2012</year><volume>256</volume><issue>1</issue><fpage>18</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1097/SLA.0b013e318256be72</pub-id><pub-id pub-id-type="pmid">22580944</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkes</surname><given-names>NJ</given-names></name><name><surname>Woolf</surname><given-names>R</given-names></name><name><surname>Mutch</surname><given-names>M</given-names></name><name><surname>Mallett</surname><given-names>SV</given-names></name><name><surname>Peachey</surname><given-names>T</given-names></name><name><surname>Stephens</surname><given-names>R</given-names></name><etal/></person-group><article-title>The effects of balanced versus saline-based hetastarch and crystalloid solutions on acid-base and electrolyte status and gastric mucosal perfusion in elderly surgical patients</article-title><source>Anesth Analg</source><year>2001</year><volume>93</volume><issue>4</issue><fpage>811</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1097/00000539-200110000-00003</pub-id><pub-id pub-id-type="pmid">11574338</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>AD</given-names></name><name><surname>Schermer</surname><given-names>CR</given-names></name><name><surname>Lobo</surname><given-names>DN</given-names></name><name><surname>Munson</surname><given-names>SH</given-names></name><name><surname>Khangulov</surname><given-names>V</given-names></name><name><surname>Hayashida</surname><given-names>DK</given-names></name><etal/></person-group><article-title>Impact of intravenous fluid composition on outcomes in patients with systemic inflammatory response syndrome</article-title><source>Crit Care</source><year>2015</year><volume>19</volume><fpage>334</fpage><pub-id pub-id-type="doi">10.1186/s13054-015-1045-z</pub-id><pub-id pub-id-type="pmid">26370823</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barmparas</surname><given-names>G</given-names></name><name><surname>Liou</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>D</given-names></name><name><surname>Fierro</surname><given-names>N</given-names></name><name><surname>Bloom</surname><given-names>M</given-names></name><name><surname>Ley</surname><given-names>E</given-names></name><etal/></person-group><article-title>Impact of positive fluid balance on critically ill surgical patients: a prospective observational study</article-title><source>J Crit Care</source><year>2014</year><volume>29</volume><issue>6</issue><fpage>936</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.jcrc.2014.06.023</pub-id><pub-id pub-id-type="pmid">25085510</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Oliveira</surname><given-names>FS</given-names></name><name><surname>Freitas</surname><given-names>FG</given-names></name><name><surname>Ferreira</surname><given-names>EM</given-names></name><name><surname>de Castro</surname><given-names>I</given-names></name><name><surname>Bafi</surname><given-names>AT</given-names></name><name><surname>de Azevedo</surname><given-names>LC</given-names></name><etal/></person-group><article-title>Positive fluid balance as a prognostic factor for mortality and acute kidney injury in severe sepsis and septic shock</article-title><source>J Crit Care</source><year>2015</year><volume>30</volume><issue>1</issue><fpage>97</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/j.jcrc.2014.09.002</pub-id><pub-id pub-id-type="pmid">25269788</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasselbalch</surname><given-names>KA</given-names></name></person-group><article-title>Die Berechnung der Wasserstoffzahl des Blutes aus der freien und gebundenen Kohlens&#x000e4;ure desselben, und die Sauerstoffbindung des Blutes als Funktion der Wasserstoffzahl</article-title><source>Biochem Z</source><year>1917</year><volume>78</volume><fpage>112</fpage><lpage>4</lpage></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Astrup</surname><given-names>P</given-names></name><name><surname>Joergensen</surname><given-names>K</given-names></name><name><surname>Andersen</surname><given-names>OS</given-names></name><name><surname>Engl</surname><given-names>K</given-names></name></person-group><article-title>The acid-base metabolism, a new approach</article-title><source>Lancet</source><year>1960</year><volume>1</volume><issue>7133</issue><fpage>1035</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(60)90930-2</pub-id><pub-id pub-id-type="pmid">13794904</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emmett</surname><given-names>M</given-names></name><name><surname>Narins</surname><given-names>RG</given-names></name></person-group><article-title>Clinical use of the anion gap</article-title><source>Medicine</source><year>1977</year><volume>56</volume><issue>1</issue><fpage>38</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1097/00005792-197756010-00002</pub-id><pub-id pub-id-type="pmid">401925</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>PA</given-names></name></person-group><source>How to understand acid-base. A quantitative acid-base primer for biology and medicine</source><year>1981</year><publisher-loc>New York/Oxford</publisher-loc><publisher-name>Elsevier</publisher-name></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>PA</given-names></name></person-group><article-title>Modern quantitative acid-base chemistry</article-title><source>Can J Physiol Pharmacol</source><year>1983</year><volume>61</volume><issue>12</issue><fpage>1444</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1139/y83-207</pub-id><pub-id pub-id-type="pmid">6423247</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seifter</surname><given-names>JL</given-names></name></person-group><article-title>Integration of acid-base and electrolyte disorders</article-title><source>N Engl J Med</source><year>2015</year><volume>372</volume><issue>4</issue><fpage>391</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">25607440</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rehm</surname><given-names>M</given-names></name><name><surname>Conzen</surname><given-names>PF</given-names></name><name><surname>Peter</surname><given-names>K</given-names></name><name><surname>Finsterer</surname><given-names>U</given-names></name></person-group><article-title>The Stewart model. &#x0201c;Modern&#x0201d; approach to the interpretation of the acid-base metabolism</article-title><source>Anaesthesist</source><year>2004</year><volume>53</volume><issue>4</issue><fpage>347</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1007/s00101-004-0660-x</pub-id><pub-id pub-id-type="pmid">15088097</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Figge</surname><given-names>J</given-names></name><name><surname>Rossing</surname><given-names>TH</given-names></name><name><surname>Fencl</surname><given-names>V</given-names></name></person-group><article-title>The role of serum proteins in acid-base equilibria</article-title><source>J Lab Clin Med</source><year>1991</year><volume>117</volume><issue>6</issue><fpage>453</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">2045713</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>TJ</given-names></name><name><surname>Venkatesh</surname><given-names>B</given-names></name></person-group><article-title>Designing &#x0201c;balanced&#x0201d; crystalloids</article-title><source>Crit Care Resusc</source><year>2003</year><volume>5</volume><issue>4</issue><fpage>284</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">16563119</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>TJ</given-names></name><name><surname>Venkatesh</surname><given-names>B</given-names></name><name><surname>Hall</surname><given-names>J</given-names></name></person-group><article-title>Crystalloid strong ion difference determines metabolic acid-base change during in vitro hemodilution</article-title><source>Crit Care Med</source><year>2002</year><volume>30</volume><issue>1</issue><fpage>157</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1097/00003246-200201000-00022</pub-id><pub-id pub-id-type="pmid">11902256</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hofmann-Kiefer</surname><given-names>KF</given-names></name><name><surname>Chappell</surname><given-names>D</given-names></name><name><surname>Kammerer</surname><given-names>T</given-names></name><name><surname>Jacob</surname><given-names>M</given-names></name><name><surname>Paptistella</surname><given-names>M</given-names></name><name><surname>Conzen</surname><given-names>P</given-names></name><etal/></person-group><article-title>Influence of an acetate- and a lactate-based balanced infusion solution on acid base physiology and hemodynamics: an observational pilot study</article-title><source>Eur J Med Res</source><year>2012</year><volume>17</volume><fpage>21</fpage><pub-id pub-id-type="doi">10.1186/2047-783X-17-21</pub-id><pub-id pub-id-type="pmid">22769740</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zazzo</surname><given-names>JF</given-names></name><name><surname>Troche</surname><given-names>G</given-names></name><name><surname>Ruel</surname><given-names>P</given-names></name><name><surname>Maintenant</surname><given-names>J</given-names></name></person-group><article-title>High incidence of hypophosphatemia in surgical intensive care patients: efficacy of phosphorus therapy on myocardial function</article-title><source>Intensive Care Med</source><year>1995</year><volume>21</volume><issue>10</issue><fpage>826</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1007/BF01700966</pub-id><pub-id pub-id-type="pmid">8557871</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buell</surname><given-names>JF</given-names></name><name><surname>Berger</surname><given-names>AC</given-names></name><name><surname>Plotkin</surname><given-names>JS</given-names></name><name><surname>Kuo</surname><given-names>PC</given-names></name><name><surname>Johnson</surname><given-names>LB</given-names></name></person-group><article-title>The clinical implications of hypophosphatemia following major hepatic resection or cryosurgery</article-title><source>Arch Surg</source><year>1998</year><volume>133</volume><issue>7</issue><fpage>757</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1001/archsurg.133.7.757</pub-id><pub-id pub-id-type="pmid">9688005</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>J</given-names></name><name><surname>Kogan</surname><given-names>A</given-names></name><name><surname>Sahar</surname><given-names>G</given-names></name><name><surname>Lev</surname><given-names>S</given-names></name><name><surname>Vidne</surname><given-names>B</given-names></name><name><surname>Singer</surname><given-names>P</given-names></name></person-group><article-title>Hypophosphatemia following open heart surgery: incidence and consequences</article-title><source>Eur J Cardiothorac Surg</source><year>2004</year><volume>26</volume><issue>2</issue><fpage>306</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.ejcts.2004.03.004</pub-id><pub-id pub-id-type="pmid">15296888</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salem</surname><given-names>RR</given-names></name><name><surname>Tray</surname><given-names>K</given-names></name></person-group><article-title>Hepatic resection-related hypophosphatemia is of renal origin as manifested by isolated hyperphosphaturia</article-title><source>Ann Surg</source><year>2005</year><volume>241</volume><issue>2</issue><fpage>343</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1097/01.sla.0000152093.43468.c0</pub-id><pub-id pub-id-type="pmid">15650646</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>R</given-names></name><name><surname>Shiu</surname><given-names>MH</given-names></name></person-group><article-title>Hypophosphatemia after major hepatic resection</article-title><source>Surgery</source><year>1992</year><volume>111</volume><issue>3</issue><fpage>281</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">1311873</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giovannini</surname><given-names>I</given-names></name><name><surname>Chiarla</surname><given-names>C</given-names></name><name><surname>Nuzzo</surname><given-names>G</given-names></name></person-group><article-title>Pathophysiologic and clinical correlates of hypophosphatemia and the relationship with sepsis and outcome in postoperative patients after hepatectomy</article-title><source>Shock</source><year>2002</year><volume>18</volume><issue>2</issue><fpage>111</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1097/00024382-200208000-00003</pub-id><pub-id pub-id-type="pmid">12166771</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geerse</surname><given-names>DA</given-names></name><name><surname>Bindels</surname><given-names>AJ</given-names></name><name><surname>Kuiper</surname><given-names>MA</given-names></name><name><surname>Roos</surname><given-names>AN</given-names></name><name><surname>Spronk</surname><given-names>PE</given-names></name><name><surname>Schultz</surname><given-names>MJ</given-names></name></person-group><article-title>Treatment of hypophosphatemia in the intensive care unit: a review</article-title><source>Crit Care</source><year>2010</year><volume>14</volume><issue>4</issue><fpage>R147</fpage><pub-id pub-id-type="doi">10.1186/cc9215</pub-id><pub-id pub-id-type="pmid">20682049</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>HJ</given-names></name><name><surname>Wu</surname><given-names>MS</given-names></name></person-group><article-title>Extreme hyperphosphatemia and hypocalcemic coma associated with phosphate enema</article-title><source>Intern Med</source><year>2008</year><volume>47</volume><issue>7</issue><fpage>643</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.2169/internalmedicine.47.0704</pub-id><pub-id pub-id-type="pmid">18379152</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cockcroft</surname><given-names>DW</given-names></name><name><surname>Gault</surname><given-names>MH</given-names></name></person-group><article-title>Prediction of creatinine clearance from serum creatinine</article-title><source>Nephron</source><year>1976</year><volume>16</volume><issue>1</issue><fpage>31</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1159/000180580</pub-id><pub-id pub-id-type="pmid">1244564</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacob</surname><given-names>M</given-names></name><name><surname>Chappell</surname><given-names>D</given-names></name><name><surname>Hofmann-Kiefer</surname><given-names>K</given-names></name><name><surname>Helfen</surname><given-names>T</given-names></name><name><surname>Schuelke</surname><given-names>A</given-names></name><name><surname>Jacob</surname><given-names>B</given-names></name><etal/></person-group><article-title>The intravascular volume effect of Ringer&#x02019;s lactate is below 20%: a prospective study in humans</article-title><source>Crit Care</source><year>2012</year><volume>16</volume><issue>3</issue><fpage>R86</fpage><pub-id pub-id-type="doi">10.1186/cc11344</pub-id><pub-id pub-id-type="pmid">22591647</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rehm</surname><given-names>M</given-names></name><name><surname>Hulde</surname><given-names>N</given-names></name><name><surname>Kammerer</surname><given-names>T</given-names></name><name><surname>Meidert</surname><given-names>AS</given-names></name><name><surname>Hofmann-Kiefer</surname><given-names>K</given-names></name></person-group><article-title>State of the art in fluid and volume therapy: a user-friendly staged concept. English version</article-title><source> Anaesthesist</source><year>2017</year><volume>66</volume><issue>3</issue><fpage>153</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1007/s00101-017-0272-x</pub-id><pub-id pub-id-type="pmid">28213648</pub-id></element-citation></ref></ref-list></back></article>